P

Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403

Watchlist Manager
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Watchlist
Price: 21.45 CNY -3.77% Market Closed
Market Cap: 15.6B CNY
Have any thoughts about
Pacific Shuanglin Bio pharmacy Co Ltd?
Write Note

Pacific Shuanglin Bio pharmacy Co Ltd
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pacific Shuanglin Bio pharmacy Co Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
P
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Note Receivable
ÂĄ600m
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Note Receivable
ÂĄ71.7m
CAGR 3-Years
-20%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Note Receivable
ÂĄ50m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pacific Shuanglin Bio pharmacy Co Ltd
Glance View

Market Cap
15.7B CNY
Industry
Biotechnology

Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in the production and marketing of pharmaceutical products. The company is headquartered in Zhanjiang, Guangdong and currently employs 1,627 full-time employees. The firm's main products are human albumin, intravenous immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin and rabies immunoglobulin. The firm mainly operates its business in the domestic market.

Intrinsic Value
32.18 CNY
Undervaluation 33%
Intrinsic Value
Price
P

See Also

What is Pacific Shuanglin Bio pharmacy Co Ltd's Note Receivable?
Note Receivable
600m CNY

Based on the financial report for Sep 30, 2024, Pacific Shuanglin Bio pharmacy Co Ltd's Note Receivable amounts to 600m CNY.

What is Pacific Shuanglin Bio pharmacy Co Ltd's Note Receivable growth rate?
Note Receivable CAGR 3Y
1%

Over the last year, the Note Receivable growth was 0%. The average annual Note Receivable growth rates for Pacific Shuanglin Bio pharmacy Co Ltd have been 1% over the past three years .

Back to Top